终末期肝病模型和吲哚菁绿清除试验联合评分对肝硬化 患者并发症发生的预测价值

doi:10.19871/j.cnki.xfcrbzz.2023.03.004

摘要/Abstract

摘要： 目的通过分析肝硬化患者终末期肝病模型（MELD）评分和吲哚菁绿清除试验（ICG_R15）评分的关系,并就ICG_R15、MELD和MELD-ICG_R15评分对患者在半年内及远期是否发生并发症的预测效能进行比较,为肝硬化患者的并发症预防及治疗时机选择提供临床依据。方法选取2017年4月至2018年4月因肝硬化入院深圳市人民医院感染内科的患者112例。观察入组患者6个月、1年、2年、3年内发生并发症的情况,统计并分析肝硬化患者MELD、MELD-ICG_R15评分分值与发生并发症的关系。使用灵敏度、特异度和受试者工作特征曲线（ROC曲线）的曲线下面积（AUC）进行评估,评价ICG_R15、MELD、MELD-ICG_R15评分对于肝硬化患者出现并发症可能性预测价值（P<0.05）。结果入组患者在6个月、1年、2年、3年的并发症发生率分别为48.2%（54/112）、50.0%（56/112）、50.9%（57/112）、50.9%（57/112）。有并发症患者和无并发症患者两组间年龄（t=-0.929,P=0.357）、性别（χ²=0.429,P=0.521）、血清肌酐值（Scr）（t=-1.229,P=0.224）和国际标准化比值（INR）（t=-1.825,P=0.069）差异无统计学意义（P>0.05）;血清总胆红素（TBil）（t=-2.869,P=0.006）、血清白蛋白（ALB）（t=4.998,P<0.001）、ICGR15（t= -5.264,P<0.001）、MELD评分（t=-4.678,P<0.001）、MELD-ICG_R15评分（t=-6.041,P<0.001）有统计学差异（P<0.05）。MELD-ICG_R15评分的AUC为0.866,95% CI为0.799~0.933,cut-off值为47.5,对应的灵敏度为0.870,特异度为0.759。纳入观察的指标中,MELD-ICG_R15评分的AUC最大,优于ICG_R15（AUC：0.824）、MELD评分（AUC：0.830）。结论 ICG_R15、MELD评分、MELD-ICG_R15评分可对于肝硬化患者6个月内及远期出现并发症进行预测,其中MELD-ICG_R15评分预测效能最佳。

关键词: 肝硬化, 并发症, 吲哚菁绿清除试验, 终末期肝病模型评分

Abstract: Objective To analyze the relationship between MELD score and ICGR15 score in patients with liver cirrhosis, and to compare the predictive efficacy of complications about ICGR15, MELD and MELD-ICGR15 score in patients with liver cirrhosis within six months and forward, so as to provide clinical basis for the choice of prevention and treatment timing of complications. Method A total of 112 patients admitted to the Department of Infectious Diseases, Shenzhen People's Hospital from April 2017 to April 2018 were enrolled. The ICGR15, MELD and MELD-ICGR15 scores of each patient were calculated. Complications within a period of time (six months,one year,two years, three years respectively)were observed. The relationship between ICGR15, MELD, MELD-ICGR15 score and complications was analyzed,to evaluate the predictive value of ICGR15, MELD and MELD-ICGR15 scores for complications in patients with cirrhosis. Sensitivity, specificity,and area under the receiver operating characteristic (ROC) curve (AUC) were used. Result The complication rate of were 48.2% (54/112)、50.0%（56/112）、50.9%（57/112）、50.9%（57/112）during six month, one year, two years, three years respectively. There was no statistically significant difference in age(t=-0.929, P=0.357), sex (χ²=0.429, P=0.521), serum creatinine (Cr) (t=-1.229, P=0.224) and INR (t=-1.825, P=0.069) between the group with and without complication. There have statistically significant differences in total bilirubin (TBil) (t=-2.869, P=0.006), serum albumin (ALB) (t=4.998, P<0.001), ICGR15(t=-5.264, P<0.001), MELD score (t=-4.678, P<0.001) and MELD-ICGR15 score(t=-6.041, P<0.001) between the two groups (P<0.05). The area under the ROC curve (AUC) of the MELD-ICGR15 score was 0.866, the 95% confidence interval was 0.799 to 0.933, the cut-off value was 47.5, the corresponding sensitivity was 0.870, and the specificity was 0.759. Incorporated in the observations among the metrics, the ROC curve of the MELD-ICGR15 score was the largest area, better than the ICGR15 (AUC: 0.824), MELD Score (AUC: 0.830),the area under the ROC curve of the MELD-ICGR15 score was the largest, better than the ICGR15 (AUC: 0.824) and MELD score(AUC: 0.830). Conclusion The ICGR15, MELD score and MELD-ICGR15 score can predict the complications in patients with cirrhosis within 6 months and forward, but the MELD-ICGR15 score is the best.

Key words: Cirrhosis of the liver, Complication, Indocyanine green clearance test, Model for end stage liver disease score

中图分类号:

R575.2

杨智, 吴伟刚, 欧鹏程, 陈洪涛, 曾芙蓉, 解东媛, 杨林, 杨桂林. 终末期肝病模型和吲哚菁绿清除试验联合评分对肝硬化患者并发症发生的预测价值[J]. 新发传染病电子杂志, 2023, 8(3): 19-24.

Yang Zhi, Wu Weigang, Ou Pengcheng, Chen Hongtao, Zeng Furong, Xie Dongyuan, Yang Lin, Yang Guilin. Predictive value of MELD-ICGR15 score for complications in patients with liver cirrhosis[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(3): 19-24.

参考文献

[1] 张豪, 邹立秋. 磁共振新技术对肝纤维化诊断的研究进展[J/CD]. 新发传染病电子杂志,2019,4(4):247-251.
[2] 罗杰棋,沈菁,郭昂,等. 磁共振IDEAL-IQ成像技术在乙型病毒性肝炎肝纤维化和早期肝硬化诊断中的应用价值[J/CD]. 新发传染病电子杂志,2021,6(4):289-293.
[3] 黄伟强. 弹性成像及血生化指标对肝纤维化的评价及研究进展[J/CD]. 新发传染病电子杂志,2017,2(2):117-121.
[4] ZIPPRICH A, KUSS O, ROGOWSKI S, et al.Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis[J]. Gut, 2010, 59: 963-968.
[5] 葛均波, 徐永健. 内科学[M].9版.北京:人民卫生出版社,2018.
[6] 陈灏珠, 林果为, 王吉耀. 实用内科学[M].15版.北京:人民卫生出版社, 2017.
[7] 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 实用肝脏病杂志, 2018, 21(1):21-31.
[8] KAMATH PS, WIESNER RH, MALINCHOC M, er al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2):464-470.
[9] 丁剑波, 李秀惠, 勾春燕, 等. 终末期肝病模型预测慢性乙型重型肝炎预后的评估[J]. 肝脏, 2018, 23(10):868-869,877.
[10] CHENG XP, ZHAO J, CHEN Y, et al.Comparison of the ability of the PDD-ICG clearance test, CTP, MELD, and MELD-Na to predict short-term and medium-term mortality in patients with decompensated hepatitis B cirrhosis[J].Eur J Gastroenterol Hepatol, 2016, 28(4):444-448.
[11] 王铭, 唐红. 吲哚菁绿清除试验的临床应用[J].临床肝胆病杂志, 2017, 33(6):1183-1187.
[12] 喻玮, 裘云庆. 肝脏储备功能评估方法的研究进展[J]. 中西医结合肝病杂志, 2013, 23(4):253-256.
[13] TAN YF, ZHANG W, JIANG L, et al.Efficacy and safety of anatomic resection versus nonanatomic resection in patients with hepatocellular carcinoma: A systemic review and meta-analysis[J]. PLoS One, 2017, 12(10):e0186930.
[14] MARK J, HUGO F, NAZ S, et al.Ability of King's College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis[J]. Clin Gastroenterol Hepatol, 2016, 14(4):516-525.
[15] WANG YY, ZHAO XH, MA L, et al.Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma[J]. J Surg Oncol, 2018, 118(3): 440-445.
[16] FENG HL, LI Q, WANG L, et al.Indocyanine green clearance test combined with MELD score in predicting the short-term prognosis of patients with acute liver failure[J]. Hepatobiliary Pancreat Dis Int, 2014, 13(3):271-275.
[17] 查锡良, 药立波. 生物化学与分子生物学[M]. 9版. 北京:人民卫生出版社, 2018.
[18] XIANG YY,SONG F,YANG XH,et al.Evaluation of the significance of hepatic functional reserve for the operation of liver cancer complicated with cirrhosis[J].J BUON,2017,22(4): 932-935.
[19] 袁满, 王丽春. 吲哚氰绿清除试验在肝病中的应用进展[J].华西医学, 2017, 32(3):471-474.
[20] 庄波, 金如燕, 厉学民, 等. 测定肝功能时吲哚菁绿清除试验的影响因素分析[J]. 肝胆胰外科杂志, 2013, 25(4):336-338.
[21] SAMIR G.Assessment of liver perfusion and function by indocyanine green in the perioperative setting and in critically ill patients[J]. J Clin Monit Comput, 2018, 32(5):787-796.
[22] EMAN MH, MOHAMED SE, ABDEL RA, et al.Hemodynamic Changes of Hepatic & Renal vessels In Systemic Bacterial Infection with Fever in HCV Related Cirrhosis[J]. Infect Disord Drug Targets, 2020, 20(4):511-516.
[23] TANG YH, JU WQ, CHEN MG, et al.The combination of indocyanine green clearance test and model for end-stage liver disease score predicts early graft outcome after liver transplantation[J]. J Clin Monit Comput, 2018, 32(3):471-479.
[24] 江甫柱, 倪鎏达, 胡峰, 等. MELD-ICG对HBV/HCV肝硬化预后的评估价值[J]. 肝脏, 2013, 18(7):439-443.
[25] WU SL, ZHENG YX, TIAN ZW, et al.Scoring systems for prediction of mortality in decompensated liver cirrhosis: A meta-analysis of test accuracy[J]. World J Clin Cases, 2018, 6(15):995-1006.